# Chromium Glucose Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/chromium-glucose-randomized-trial-evidence-review
Category: evidence-review
Summary: Chromium Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are syste
Last reviewed: 2026-05-22
Reviewed by: Migaku Evidence Review
# Chromium Glucose Randomized Trial: What the Evidence Says

## Quick Answer

Chromium Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials | systematic review | 1 | 2026-01-24 | 10.1186/s12902-025-02158-x |
| Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential | narrative review | 3 | 2026-02-10 | 10.3389/fendo.2026.1766838 |

## What The Sources Report

- Reduced insulin receptor sensitivity leads to a significant decline in insulin efficacy during glucose metabolism, further promoting hyperinsulinemia. [Ye Jiahui (2026); evidence level 1]
- While women in developing countries may display lean PCOS phenotypes with severe reproductive dysfunction, women in industrialized countries frequently present with obesity-associated insulin resistance and metabolic syndrome. [Natarajan Madhumitha (2026); evidence level 3]
- Given the growing body of evidence linking micronutrient status to PCOS pathophysiology, there is a need to consolidate existing mechanistic and clinical evidence. [Natarajan Madhumitha (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For chromium glucose randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Ye Jiahui (2026). Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. DOI: 10.1186/s12902-025-02158-x. PMCID: PMC12955229. PMID: 41580698. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12955229/
- Natarajan Madhumitha (2026). Micronutrients in polycystic ovary syndrome: molecular pathways, deficiencies, and therapeutic potential. DOI: 10.3389/fendo.2026.1766838. PMCID: PMC12929159. PMID: 41743556. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12929159/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.